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Abstract
Blood clotting proceeds through the sequential proteolytic activation of a series of serine proteases,
culminating in thrombin cleaving fibrinogen into fibrin. The serine protease inhibitors (serpins)
antithrombin (AT) and protein C inhibitor (PCI) both inhibit thrombin in a heparin-accelerated
reaction. Heparin binds to the positively charged D-helix of AT and H-helix of PCI. The H-helix of
AT is negatively charged, and it was mutated to contain neutral or positively charged residues to see
if they contributed to heparin stimulation or protease specificity in AT. To assess the impact of the
H-helix mutations on heparin stimulation in the absence of the known heparin binding site, negative
charges were also introduced in the D-helix of AT. AT with both positively charged H- and D-helices
showed decreases in heparin stimulation of thrombin and factor Xa inhibition by 10 and five-fold
respectively, a decrease in affinity for heparin-sepharose, and a shift in the heparin template curve.
In the absence of a positively charged D-helix, changing the H-helix from neutral to positively
charged increased heparin stimulation of thrombin inhibition 21-fold, increased heparin affinity and
restored a normal maximal heparin concentration for inhibition. (Word Count = 187)
Keywords
thrombin; factor Xa; thrombomodulin; coagulation; serpin
1. Introduction
The blood coagulation cascade consists of the sequential proteolytic activation of serine
proteases. The cascade is regulated in part by heparin binding serine protease inhibitors
(serpins) including antithrombin (AT) and protein C inhibitor (PCI) [1,2]. Serpins function by
the insertion of a reactive site loop into the active site of the target serine protease. When the
protease cleaves the loop, the serpin undergoes a conformational change trapping the protease
in an inactive complex [3]. Antithrombin, PCI, heparin cofactor II (HCII), protease nexin I
(PN1) and plasminogen activator inhibitor 1 (PAI1) are all members of a sub-class of serpins
that bind to the sulfated glycosaminoglycan heparin through positively charged alpha helices,
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in most cases the D-helix [4]. The heparin binding domain of AT resides on or near the D-helix
(Figure 1): K11, R13, R24, R47, K114, K125 and R129, as determined by site directed
mutagenesis studies [5–9]. Previous experiments with AT mutants K125Q, K125M and
R129M showed decreases in heparin binding by AT, but no significant reduction in AT
inhibition of thrombin in the presence of heparin, or factor Xa in the presence of H5 [7,10–
12]. However, the simultaneous mutation of K125 and R129 to alanine or glutamate blocks
H5 stimulation of thrombin and factor Xa inhibition [13]. The role of these residues in heparin
binding has been confirmed by co-crystallization of trimolecular complexes of thrombin,
heparin and AT [14,15]. Among the heparin-binding serpins, PCI is unique in that heparin
binds to the positively charged H-helix residues (Figure 1) R269, K270, K276 and K277
[16]. Alignment of the D and H-helices of the five heparin-binding serpins reveals that most
have a positively charged D-helix with the exception of PCI which has a positively charged
H-helix. The H-helices of PAI1, PN1 and HCII are all net positive, while the H-helix of AT
contains only negatively charged residues which are in the same position as the heparin-binding
residues in the H-helix of PCI (Figure 2).
The mechanism by which heparin stimulates serpin activation also differs between AT and
PCI. When there is no cofactor present, PCI and AT inhibit thrombin with second-order rate
constants (k2) of 18 × 103 M−1s−1 and 9 × 103 M−1s−1 respectively [1,4,17]. Heparin binds to
exosite II of thrombin and the D- or H-helix of the serpin, forming a bridge and increasing
inhibition by 30-fold with PCI and 2000-fold with AT [18,19]. Heparin binding to the D-helix
also causes a conformational change in the reactive site loop of AT that culminates with the
exposure of both the P1 Arg of AT and an exosite on the serpin for interaction with coagulation
proteases [5,6,20–25]. This conformational change contributes to stimulation of thrombin and
factor Xa inhibition by 2 and 200-fold respectively [19,24,25]. In contrast, the reactive site
loop of PCI is very flexible and always exposed to proteolytic attack, there is also no apparent
heparin induced conformational change in PCI [26].
In addition to protease inhibition by serpins, coagulation is regulated by feedback inhibition
of thrombin production. Some of the thrombin generated during coagulation binds to the
endothelial cell receptor thrombomodulin (TM). The TM-bound thrombin recognizes protein
C as a substrate, proteolytically generating activated protein C (APC). APC in turn
proteolytically degrades factors Va and VIIIa, cofactors used in thrombin production [27]. In
this manner, thrombin binding to TM activates an anticoagulant feedback loop by degrading
cofactors needed for the further generation of thrombin. The physiological importance of this
feedback loop has been demonstrated in TM deficient mice and patients with mutations in
protein C or factor V [28–30]. The serpin specificity of thrombin is also changed when it binds
to TM. AT inhibition of thrombin bound by TM is minimally changed except when chondroitin
sulfate, a heparin-like polysaccharide, is present on TM [31,32]. When thrombin is bound to
TM containing chondroitin sulfate, inhibition of the thrombin is 100-fold faster by PCI (2.4 ×
106 M−1s−1) [17] than by AT (2.8–3.6 × 104 M−1s−1) [31,33]. Although PCI was initially
identified as a specific inhibitor of APC, these results suggest that the main target for PCI in
the vasculature may be the thrombin-TM complex. The EGF-like domains 5 and 6 of TM bind
to the fibrinogen binding exosite-1 of thrombin orienting it such that a negatively charged
region on EGF domain 4 of TM juxtaposes the positively charged H-helix of PCI [34]. If the
H-helix of AT is mutated to resemble that of PCI, AT inhibition of thrombin-TM increases 70-
fold, possibly due to interactions between negatively charged residues on EGF4 of TM and the
now positively charged H-helix of AT [34].
While performing these experiments, we noted that AT with a positively charged H-helix also
had a decrease in heparin stimulation of thrombin inhibition. To determine the role of a
negatively charged H-helix on the function of AT, we mutated the D- and H-helices of AT to
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the residues in the corresponding helices of PCI. These mutants were then used to determine
the role of the AT H-helix in heparin dependent protease inhibition.
2. Materials and Methods
Plasmid Construction
Wild-type AT cDNA [35] was excised from the plasmid pKT218-AT (ATCC) with PstI. A
His-6 tag (CAC)6 and BamHI restriction site were added to the 3′ end of the cDNA by PCR
amplification. The cDNA was ligated into pGEM3Zf(+) at the PstI and BamHI restriction sites.
Plasmids were isolated from E. coli using a QIAprep Miniprep Kit (QIAgen, Valencia, CA).
Site-directed Mutagenesis
Specific mutations were generated with the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). The following mutations were made; AT-Dneg, K125E, R129E;
AT-Hpos, D309K, E310K, E312K, E313K; AT-Hneut, D309N, E310Q, E312Q, E313Q (Figure
2). All mutations were confirmed by DNA sequencing using a BigDye dideoxy sequencing
kit. Double mutants were generated by sub-cloning the H-helix mutations into the baculovirus
transfer vector pVL1392 (pVL-AT) containing the D-helix mutations using an NcoI site in the
AT cDNA.
Expression and Purification of AT
pVL-AT containing either the wild-type or mutant AT cDNAs were cotransfected with
Baculogold Autographa californica polyhedrosis virus DNA into Sf9 (Spodoptera
frugiperda) host insect cells in TMN-FH complete media using the Baculovirus Expression
Vector System (PharMingen, San Diego, CA). Amplified viral stocks were used to infect
shaking cultures of Sf9 TriEx cells (Novagen, Madison, WI) in Insect-Xpress serum-free
medium (BioWhittaker) supplemented with 1mM L-glutamine, 2.5μg/ml fungizone and 5μg/
ml gentamicin. Three days post-infection media containing recombinant AT was collected.
Proteins with a His6 tag were loaded onto a nickel agarose column equilibrated with buffer
(0.3M NaCl, 50mM sodium phosphate, pH 7.4) containing 0.01M imidazole. The column was
washed with buffer until baseline was established, and then washed with buffer containing
0.05M imidazole and the rAT eluted with buffer containing 0.25M imidazole. The fraction was
adjusted to 10mM EDTA and diluted to 0.1M NaCl with 0.01M Tris. Proteins were then
purified by heparin affinity chromatography. Unbound proteins were eluted with TBS (0.01M
Tris, 0.02% azide, 0.1M NaCl, pH 7.4) and the rAT was then eluted with TBS containing 2M
NaCl and dialyzed against TBS to remove excess salt. Fractions containing rAT were then
loaded onto a Q-sepharose column and eluted in a 0-0.6M NaCl gradient. Fractions containing
AT activity were dialyzed against TBS, concentrated and adjusted to 0.1% PEG before storing
at −80°C.
Serine Protease Inhibition Assays
The rates of inhibition of thrombin in the presence and absence of heparin were measured using
discontinuous assays under pseudo-first order rate conditions as described previously [17,36].
Proteins were diluted in TBS buffer containing 0.1 mg/ml BSA, 0.1% PEG 8000, and 0.01%
azide to a final reaction volume of 50μl. Thrombin (0.5–2nM) and a 10-fold molar excess of
AT were incubated together (15 sec. to 30 min. based on reaction rate), followed by the addition
of 50 μl of Spectrozyme TH (SpTH) (American Diagnostica, Greenwich, CT) with 1 mg/ml
Polybrene was added to the substrate to block further heparin binding during substrate
development. For heparin template curve data, varying concentrations (0–1000 μg/ml) of
unfractionated heparin (Sigma, St. Louis, MO) were used. Substrate was added and the
microtiter plates were centrifuged for 10 min at 1000 × g to remove precipitated heparin/
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polybrene complexes in the 100 and 1000 μg/ml heparin reactions and the supernatants
transferred to new plates to measure absorbance. For subsequent assays in the presence of
heparin the optimal concentration for each protein was used. Factor Xa assays were performed
in a similar manner as the thrombin assays, using 2nM protease, 20nM AT or 100nM PCI, and
5nM heparin pentasaccharide (H5, provided by Steve Olson, University of Illinois-Chicago)
or 5 μg/ml heparin for 5 to 60 minutes depending on reaction rate. Residual factor Xa activity
was measured by addition of 50μl of 400μM Spectrozyme FXa. Second-order rate constants
of thrombin inhibition were determined using the equation: kobs = (−ln (A/A0))/tI, where A is
the absorbance of the inhibited sample at 405nm, A0 is the absorbance of uninhibited sample,
t is time of reaction in seconds and I is the concentration of AT in M [17,36]. All assays were
performed in triplicate in two to five separate experiments.
Stoichiometry of Inhibition Assays
Stoichiometry of inhibition (SI) was measured using 10nM thrombin incubated with AT alone
or in the presence of heparin (5μg/ml). Assays without heparin were performed with 0.1 mg/
ml polybrene in the buffer to neutralize any traces of heparin in the sample. AT concentrations
ranged from 5 to 100nM. Assays with heparin were incubated for one hour and those with AT
alone were incubated for 16 hours. Substrate was added as described above, residual thrombin
activity plotted versus AT concentration and the x-intercept calculated by least-squares linear
regression. Second order rate constants of thrombin inhibition were multiplied by their




The wild type recombinant AT (rAT) and mutant proteins were successfully expressed in insect
cells using the Baculovirus expression system. Immunoblots of the media from the co-
transfections demonstrated that the rAT had not been degraded and the molecular weight of
the rAT was 51 kD, less than the 58 kD for human plasma AT due to previously reported
differences in glycosylation [37]. The rAT-HPos and rAT-HNeut proteins were purified using
heparin sepharose. The rAT-DNegHPos and rAT-DNegHNeut proteins could not be completely
purified with heparin sepharose due to a decrease in heparin binding, and a polyhistidine tag
was added to the proteins, allowing for nickel agarose chromatography prior to heparin
sepharose to improve purity. All rAT proteins eluted from heparin-Sepharose at greater than
1.0M NaCl with the following exceptions; rAT-HPos eluted at 0.6M NaCl, rAT-DNegHPos-
His6 eluted at 0.4M NaCl, and rAT-DNegHNeut-His6 eluted at 0.2M NaCl.
Inhibition of Thrombin
Plasma AT, rAT and the mutants displayed a traditional bell shaped heparin dependence of
inhibition of thrombin with optimal thrombin inhibition at a heparin concentration of 5 μg/ml
(Figure 3). The only exceptions were the rAT-HPos and rAT-DNegHNeut-His6 mutants, which
had shifts in optimal heparin concentrations to 1 μg/ml and 10 μg/ml respectively. Wild-type
rAT and plasma AT both showed approximately 3000-fold acceleration of thrombin inhibition
in the presence of heparin (Table 1). Recombinant AT activity expressed was reduced 2.5-fold
relative to purified human AT, consistent with previous results from baculovirus expression
of AT [37,38]. rAT-His6 showed a four-fold loss in heparin-stimulated thrombin inhibition
when compared to rAT, mostly due to an increase in inhibition in the absence of heparin, and
an increase in SI in the presence of heparin. This is consistent with the observation that addition
of a C-terminal His tag on AT partially interferes with heparin stimulation of thrombin
inhibition [39].
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Generating an AT with positively charged D- and H-helices, rAT-HPos, led to a six-fold
increase in inhibition of thrombin in the absence of heparin, and 10-fold decrease in thrombin
inhibition in the presence of heparin relative to rAT. Changing the same H-helix residues to
neutral amino acids led to Table 1 smaller two-fold changes in thrombin inhibition in the
absence and presence of heparin (). Both mutants had slightly increased SI values relative to
rAT, indicating that these mutants have increased reactivity with the protease in the substrate
pathway of the reaction.
Changing D-helix residues to negatively charged residues in rAT-DNegHNeut-His6, did not
affect inhibition in the absence of heparin, but abolished heparin binding and stimulation of
thrombin inhibition, consistent with published results from the mutation K125E, R129E [13].
Adding a positively charged H-helix, rAT-DNegHPos-His6, restored a 21-fold increase in
thrombin inhibition with heparin. However, the rate is still 30-fold lower than that of rAT-
His6. Interestingly, the rate of thrombin inhibition by rAT-DNegHPos-His6 was only two-fold
less than that of rAT-HPos, which has an intact D-helix (Table 1)
Inhibition of Factor Xa
To ensure that the H-helix mutants were not affecting the conformation of the heparin binding
domain of the D-helix, inhibition of factor Xa was measured in the presence of 0–5nM H5.
The wild-type and H-helix mutant ATs all showed similar rates of inhibition of factor Xa with
increasing concentration of H5 (Figure 4). In contrast the two D-helix mutants had no
enhancement of inhibition of factor Xa in the presence of H5. This was also confirmed by
measuring the stimulation of factor Xa inhibition of each AT mutant in the presence of H5.
Proteins with a normal D-helix showed 30-fold stimulation while those with negatively charged
D-helices had a 10-fold decrease in stimulation. These are not maximum stimulations of Xa
inhibition, as only 5nM H5 was used. The rAT-HPos mutant also showed a two-fold increase
in inhibition of factor Xa relative to rAT in the presence or absence of H5 (Table II).
Each AT mutant was also assayed for stimulation of factor Xa in the presence of full-length
heparin. The trend was similar to that observed for heparin stimulation of thrombin inhibition
(Table II). The wild-type ATs and rAT-HNeut had similar fold stimulations in the presence of
heparin, while rAT-HPos had a five-fold decrease in stimulation compared to the control.
Changing D-helix residues to negatively charged residues in rAT-DNegHNeut-His6, did not
affect factor Xa inhibition in the absence of heparin, but abolished heparin stimulation of factor
Xa inhibition. Adding back a positively charged H-helix, rAT-DNegHPos-His6, restored a six-
fold increase in factor Xa inhibition with heparin.
4. Discussion
PCI is unique among serpins in binding heparin through the H-helix, while the other heparin-
binding serpins bind heparin through the D-helix. AT is unique in that its H-helix residues are
negatively charged, while the other heparin-binding serpins have net positively charged H-
helixes. In addition to these structural differences, AT is primarily an anticoagulant, inhibiting
thrombin, factor IXa and factor Xa, while PCI is primarily a procoagulant in the blood,
inhibiting both the formation and activity of APC and thrombin-TM. Our results suggest that
the location of the heparin-binding sites may play an important role in determining the target
protease specificity and thus the procoagulant and anticoagulant functions of these two serpins
in the clotting cascade.
In the absence of heparin, PCI is better than AT at inhibiting thrombin and factor Xa. This is
thought in part to be due to PCI having a more extended reactive site loop, and the orientation
of the P1 Arg away from the body of the serpin (Figure 1). However, heparin stimulates
thrombin inhibition by AT >2000-fold, compared with a 30-fold increase for PCI. The trend
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was even more striking with factor Xa, where heparin stimulated AT inhibition 700-fold, yet
actually decreased PCI inhibition three-fold. When heparin binds to the positively charged D
helix of AT the helix elongates, extending the reactive site loop and exposing the P1 Arg which
stimulates thrombin and Xa inhibition. Olson and Chuang have speculated that the reactive
loop sequence of AT is not optimal for recognition by thrombin and factor Xa as a mechanism
to prevent recognition by APC, thus ensuring that AT functions as an effective anticoagulant
[25]. Thus, when heparin binds to the D-helix of AT, the resulting heparin-induced
conformational change and the bridging effect of long chain heparins are responsible for
switching AT from a weak to a strong anticoagulant. In contrast, when heparin binds to the H-
helix of PCI, no major conformational change is thought to occur, and the only stimulation of
thrombin inhibition is through a bridging mechanism, favoring PCI’s role as a procoagulant.
The recent crystal structure of intact PCI (Figure 1) reveals an exposed loop in the absence of
heparin, supporting this theory (26).
When the H-helix of AT was changed to more closely resemble the H-helix of PCI, in AT-
Hpos, heparin acceleration of thrombin inhibition was reduced 10-fold, and factor Xa inhibition
five-fold, to values closer to that of PCI. Making these same H-helix residues neutral, AT-
Hneut, decreased heparin stimulation of thrombin two-fold and had no effect on factor Xa
inhibition, suggesting that the change was mostly due to the addition of positive charges to the
H-helix of AT, rather than the loss of negative charges. It is plausible that a new competitive
heparin-binding site was created on the H-helix of AT, because the heparin template curve for
the AT-Hpos mutant shifted slightly to the left, indicating that less heparin was needed to
achieve maximal heparin stimulation. This was also consistent with a decrease in maximal rate
of thrombin inhibition, as heparin bound to the H-helix may not be able to bind to the D-helix,
thus blocking extension of the reactive site loop of AT.
To block heparin stimulation of AT through binding to the D-helix, mutation were generated
in a rAT-His6 background. The introduction of a negatively charged N-terminal tag in AT-
His6 improved the reactivity of the serpin with thrombin in the absence of heparin, possibly
through its interaction with a complementary site of the protease. However, such an interaction
does not appear to occur for the mutant AT with factor Xa, possibly accounting for the
differential extent of the cofactor effect of heparin in stimulating the AT-His6 inhibition of
these proteases. As expected, the mutations K125E and R129E, in rAT-DNegHNeut-His6,
resulted in decreased heparin stimulation of thrombin inhibition, no H5 stimulation of factor
Xa inhibition, and a shift in the heparin concentration for optimal thrombin inhibition,
indicating that more heparin was necessary to stimulate thrombin inhibition. Adding a
positively charged H-helix to this D-helix mutant (rAT-DNegHPos-His6) restored normal
optimal heparin concentrations for thrombin inhibition. Heparin stimulation of thrombin
inhibition also increased to 20-fold, similar to that seen for PCI, which also has a negatively
charged D-helix and positively charged H-helix. These rates of inhibition are consistent with
a new heparin binding site on the H-helix, that can increase thrombin inhibition through a
bridging mechanism, as seen with PCI, but not through the traditional conformational change
seen in AT.
An alternative explanation is that a negatively charged H-helix in AT reduces the rate of
inhibition of thrombin alone in the absence of heparin by a charge-charge repulsion mechanism
between negatively charged residues in the AT H-helix and possibly the 60-D loop of thrombin.
In support of this hypothesis, the structure of the ternary AT-thrombin-heparin complex shows
that Asp-60 of thrombin is very close to Glu-313 of AT (~7Å). Thus, a repulsive interaction
between these two negatively charged residues may also account for the slower reactivity of
the serpin with thrombin in the absence of heparin.
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AT is unique among the heparin binding serpins in that it has a negatively charged H-helix.
Reversing the charge of this helix to resemble that of PCI decreases heparin stimulation of
thrombin inhibition and increases the rate of inhibition of thrombin-TM. Both of these changes
cause AT-Hpos to behave more like PCI than AT. Thus the negative charges on the H-helix of
AT may add to its anticoagulant activity by preventing heparin binding to the H-helix, and by
repelling the EGF4 domain of TM and thus not inhibiting APC formation.
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Crystal structures of intact AT, PDB entry 1AZX (left) and PCI, PDB entry 2OL2 (right) with
D-helices highlighted in red and H-helices in yellow. The P1 Arg on the reactive site loop is
shown in stick with van der Waal radii.
Gonzales et al. Page 10














Alignments of D- and H-helices of the heparin-binding serpins, PAI1, PN1, HCII, AT, and
PCI. Conserved residues are blue, positively charged are red and negatively charged are green.
The AT residues changed in this study are indicated by arrows. The columns to the right of
each alignment indicate the total numbers of positive and negative residues in each aligned
sequence.
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Thrombin (1nM) was incubated with 10nM of each of the following antithrombins in the
presence of increasing concentrations of heparin; human AT( ), wild type rAT (■), wild type
rAT-His6 (▲), rAT-Hneut (●), rAT-Hpos (□), rAT-DnegHpos-His6 (△), rAT-DposHneut-His6
(◇). Reactions were stopped after 15 seconds to 15 minutes at room temperature by the
addition of Spectrozyme TH and polybrene, final concentrations 0.2 mM and 0.1 mg/ml
respectively. Pseudo first-order rate constants (kobs) were calculated from the remaining
activity of enzymes as described under “Experimental Procedures”
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Factor Xa (2 nM) was incubated with 20nM of each of the following antithrombins in the
presence of increasing concentrations of heparin pentasaccharide (H5); wild type rAT (■), wild
type rAT-His6 (▲), rAT-Hneut (●), rAT-Hpos (□), rAT-DnegHpos-His6 (△), rAT-DposHneut-
His6 (◇). Reactions were stopped after 5 minutes at room temperature by the addition of
Spectrozyme FX and polybrene, final concentrations 0.2 mM and 0.1 mg/ml respectively.
Pseudo first-order rate constants (kobs) were calculated from the remaining activity of enzymes
as described under “Experimental Procedures”.
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